Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn about a recent article by Valérie Gounant et al, published in JTO Clinical and Research Reports:
“Poor PS, high PD-L1—can IO still work?
IFCT-1802 SAVIMMUNE (Ph2) evaluated 1L durvalumab in stage IV NSCLC with ECOG PS 2–3 and PD-L1 ≥25%.
- Grade ≥3 TRAEs (8 wks): 10%
- ORR: 26%
- 1-yr OS: 40%
- PS improvement at 8 wks: 44%
Important data for a population often excluded from trials.”
Title: Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Authors: Valérie Gounant, Laurent Greillier, Céline Mascaux, François Pinquie, Delphine Carmier, Lionel Moreau, Benoît Roch, Didier Debieuvre, Xavier Dhalluin, Etienne Giroux-Leprieur, Elodie Berton, Audrey Rabeau, Judith Raimbourg, Adrien Dixmier, Charles Naltet, Antoine Khalil, Lynn Ezzeddine, Mostafa El Hajjam, Alexandra Langlais, Franck Morin, Virginie Westeel, Gérard Zalcman, Michael Duruisseaux
Read the Full Article on JTO Clinical and Research Reports
More posts featuring Aakash Desai.